Trial Information

Evaluation of Serum Thymidine Kinase Activity in Diagnosis,Prognosis and Monitoring of Treatment in Patients With Solid Tumors

Thymidine kinase 1 (TK1) is a metabolic enzyme catalyzing the ATP-dependent phosphorylation
of thymidine to thymidine monophosphate followed by its utilization in DNA synthesis. It has
been demonstrated that activity of TK1 in the serum of cancer patients corresponds to the
amount of dividing tumor cells. Several clinical investigations clearly showed that abnormal
TK1 levels indicate tumor growth. In breast cancer, serum TK1 was shown to predict increased
risk of recurrence following surgery and may be a good marker for monitoring the response
to therapy. The measurements of TK1 were useful as a prognostic and monitoring factor in
patients with NSCLC. Unfortunately, all previously used assays measuring TK1 activity showed
relatively low analytical sensitivity. Recently, the novel high sensitive non-radioactive
TK1 assay (DiviTum) has been developed. With this assay tumour growth may be detected at an
earlier stage of disease and smaller amounts of residual disease may be detected during and
after therapy.